Ticagrelor - Latest Advances

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.

Journal: Stroke

Published: January 13, 2026

Ticagrelor-induced sinus pause: an adenosine-driven side effect.

Journal: BMJ case reports

Published: January 12, 2026

Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study.

Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Published: January 05, 2026

Is Ticagrelor-Related Dyspnea a Liability or a Biomarker of Response?

Journal: Clinical cardiology

Published: December 29, 2025

Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis.

Journal: Pharmacogenomics

Published: December 26, 2025

Utilization of Green Analytical Chemistry Concepts in Analytical Methodologies for the Triazolopyrimidine Medicament Ticagrelor-A Review.

Journal: Critical reviews in analytical chemistry

Published: December 23, 2025

Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice.

Journal: The International journal of risk & safety in medicine

Published: December 23, 2025

Why Genetics Can't Be Ignored in Secondary Stroke Prevention: The CYP2C19 Challenge in Asia.

Journal: Stroke

Published: December 22, 2025

Differential Effect of Ticagrelor Versus Clopidogrel by Causative Classification of Stroke Classification and Vascular Cellular Adhesion Molecule-1 Level on the Risk of Recurrent Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.

Journal: Journal of the American Heart Association

Published: December 18, 2025

"Reconsidering CYP3A4/5 Genotyping for Ticagrelor Safety: Critical Appraisal of a Narrow Genetic Framework".

Journal: Clinical cardiology

Published: December 12, 2025

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: December 02, 2025

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: December 02, 2025

Filters

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.

Ticagrelor-induced sinus pause: an adenosine-driven side effect.

Ticagrelor-induced sinus pause: an adenosine-driven side effect.

Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study.

Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study.

Is Ticagrelor-Related Dyspnea a Liability or a Biomarker of Response?

Is Ticagrelor-Related Dyspnea a Liability or a Biomarker of Response?

Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis.

Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis.

Utilization of Green Analytical Chemistry Concepts in Analytical Methodologies for the Triazolopyrimidine Medicament Ticagrelor-A Review.

Utilization of Green Analytical Chemistry Concepts in Analytical Methodologies for the Triazolopyrimidine Medicament Ticagrelor-A Review.

Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice.

Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice.

Why Genetics Can't Be Ignored in Secondary Stroke Prevention: The CYP2C19 Challenge in Asia.

Why Genetics Can't Be Ignored in Secondary Stroke Prevention: The CYP2C19 Challenge in Asia.

Differential Effect of Ticagrelor Versus Clopidogrel by Causative Classification of Stroke Classification and Vascular Cellular Adhesion Molecule-1 Level on the Risk of Recurrent Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.

Differential Effect of Ticagrelor Versus Clopidogrel by Causative Classification of Stroke Classification and Vascular Cellular Adhesion Molecule-1 Level on the Risk of Recurrent Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.

"Reconsidering CYP3A4/5 Genotyping for Ticagrelor Safety: Critical Appraisal of a Narrow Genetic Framework".

"Reconsidering CYP3A4/5 Genotyping for Ticagrelor Safety: Critical Appraisal of a Narrow Genetic Framework".

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial.

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial.